Research Institute Seeks Federal Permission to Import Psilocybin and DMT
Published Date: 5/20/2025
Notice
Summary
Usona Institute wants to become an official importer of some powerful controlled substances like psilocybin and DMT. If you’re a registered manufacturer or interested party, you have until June 20, 2025, to share your thoughts or ask for a hearing. This move could impact how these substances are handled and studied in the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Application to Import Schedule I Psychedelics for Research
Usona Institute applied on May 5, 2025 to be registered to import four Schedule I substances — 5‑Methoxy‑N‑N‑dimethyltryptamine (5‑MeO‑DMT, code 7431), dimethyltryptamine (DMT, code 7435), psilocybin (code 7437), and psilocyn (code 7438) — for research and analytical purposes only. The notice says the materials will not be used for clinical trials or human consumption and that no other activities for these drug codes are authorized for this registration.
Import Does Not Cover Finished Dosage Forms for Sale
The notice explicitly states that authorization will not extend to the import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale. Approval of permit applications will occur only when the registrant's activity is consistent with 21 U.S.C. 952(a)(2).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-21413, Jefferson Burroughs, M.D.; Decision and Order
Dr. Jefferson Burroughs from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of July 31, 2026. This means Dr. Burroughs can’t legally prescribe or manage controlled drugs anymore, affecting his medical practice and patients.
2026-21414, Jan Pijanowski, M.D.; Decision and Order
Dr. Jan Pijanowski from Ohio lost his DEA registration because his medical license expired and he didn’t respond to the DEA’s notice. This means he can no longer prescribe or handle controlled substances, effective immediately. If you’re a patient or pharmacy, this change is official as of October 2026 and affects any prescriptions tied to him.
Previous / Next Documents
Previous: 2025-08996, Open Meeting of the Taxpayer Advocacy Panel's Tax Forms and Publications Project Committee
The IRS is hosting a virtual meeting on June 10, 2025, to hear your ideas on making tax forms and publications easier to use. If you’re a taxpayer, this is your chance to speak up and help improve IRS customer service. Just register by June 6 to join and share your thoughts—no money changes hands, but your input could make filing taxes simpler for everyone!
Next: 2025-08998, Importer of Controlled Substances Application: Quagen Pharmaceuticals LLC
Quagen Pharmaceuticals LLC wants to become an official importer of certain controlled drugs, including Diphenoxylate. This means they’ll be allowed to bring these substances into the U.S. for medical or research use. If anyone has concerns or wants a hearing, they must speak up by June 20, 2025, so don’t miss the deadline!